<DOC>
	<DOCNO>NCT00397098</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SR58611A ( 350 mg BID ) compare placebo prevention relapse anxiety , patient Generalized Anxiety Disorder improve 12 week treatment SR58611A . The primary objective evaluate efficacy SR58611A 350mg BID compare placebo 24 52-week treatment period . The secondary objective ass safety tolerability SR58611A patient GAD .</brief_summary>
	<brief_title>Prevention Relapse Study SR58611A Improved Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<criteria>For entry open phase : Patients suffer generalized anxiety disorder , accord Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) criterion assess Mini International Neuropsychiatric Interview ( MINI ) plus Generalized Anxiety Disorder ( GAD ) module . With total score 14item Hamilton Anxiety Rating Scale ( HAMA ) &gt; 20 V1 ( D4 ) V2 ( D1 ) . For entry doubleblind randomized phase : Improved patient HAMA score &lt; 11 V7 ( W12 ) . Inpatients . Patients diagnosis Major Depressive Disorder ( DSM IVTR ) within 6 month screen . Patients MADRS total score &gt; 18 screen baseline . Patients immediate risk suicidal behaviour . Patients current ( within 6 month ) anxiety disorder accord MINI Patients lifetime history accord MINI : Bipolar disorder , Psychotic disorder , Antisocial personality disorder . Patients current history accord MINI : Anorexia nervosa bulimia nervosa past 6 month , Alcohol substance dependence abuse past 12 month , except nicotine caffeine dependence . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Anxiety disorder , Relapse prevention</keyword>
</DOC>